Age at first cardiovascular diagnosis and risk of subsequent cardiovascular events in patients with different types of cardiovascular disease - Top-Institutions - MDSpire

Age at first cardiovascular diagnosis and risk of subsequent cardiovascular events in patients with different types of cardiovascular disease

  • By

  • Martijn M Pieterse

  • Martin Teraa

  • Manon G van der Meer

  • Ynte M Ruigrok

  • Mike J L Peters

  • Ilonca Vaartjes

  • Frank L J Visseren

  • Jannick A N Dorresteijn

  • on behalf of the UCC-SMART Study Group

  • February 2, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    University Medical Center Utrecht
    University Medical Center Utrecht

    Utrecht, Utrecht

    Key Differentiators

    • Cardiovascular Epidemiology
    • Vascular Medicine
    • Stroke Research

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, Maryland

    Key Differentiators

    • Cardiology
    • Epidemiology
    • Stroke and Vascular Neurology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Cardiology
    • Vascular Medicine
    • Clinical Epidemiology

  • #4

    Harvard Medical School / Brigham and Women’s Hospital
    Harvard Medical School / Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology
    • Vascular Medicine
    • Epidemiology

  • #5

    University of Cambridge
    University of Cambridge

    Cambridge, Cambridgeshire

    Key Differentiators

    • Cardiovascular Medicine
    • Epidemiology
    • Stroke Research

Original Source(s)

Age at first cardiovascular diagnosis and risk of subsequent cardiovascular events in patients with different types of cardiovascular disease

  • by Martijn M Pieterse, Martin Teraa, Manon G van der Meer, Ynte M Ruigrok, Mike J L Peters, Ilonca Vaartjes, Frank L J Visseren, Jannick A N Dorresteijn, on behalf of the UCC-SMART Study Group

  • February 2, 2026

Related Content

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Association between blood pressure levels and risk of stroke in patients with atrial fibrillation: results from a prospective registry in Xinjiang, China